FY2025 Earnings Forecast for BMY Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised its FY2025 earnings estimate for Bristol Myers Squibb (NYSE:BMY) from $6.54 to $6.35 per share, which is lower than the consensus estimate of $6.74.
• In addition, dividend payments of $0.62 per share have been announced, with a dividend yield of 5.7% for shareholders of record.
• Bristol Myers Squibb's stock has recently been rated with a consensus of "Hold" by analysts, with an average target price of $57.14.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Stock analysts at Leerink Partnrs cut their FY2025 earnings estimates for shares of Bristol Myers Squibb in a report released on Monday, October 13th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $6.35 per share for the year, down from their previous forecast of $6.54. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol Myers Squibb's FY2026 earnings at $5.88 EPS, FY2027 earnings at $5.83 EPS and FY2029 earnings at $5.90 EPS.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. Bristol Myers Squibb's revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.

Several other analysts also recently commented on the stock. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Bristol Myers Squibb in a report on Tuesday. Citigroup reaffirmed a "neutral" rating on shares of Bristol Myers Squibb in a report on Monday. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective for the company. in a report on Tuesday, August 5th. Finally, Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fifteen have assigned a Hold rating to the company. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and an average target price of $57.14.

Bristol Myers Squibb Stock Down 0.4%

Bristol Myers Squibb stock opened at $43.63 on Thursday. The firm has a market capitalization of $88.81 billion, a PE ratio of 17.59, a P/E/G ratio of 2.26 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The company's 50-day moving average is $46.16 and its 200-day moving average is $47.79. Bristol Myers Squibb has a fifty-two week low of $42.96 and a fifty-two week high of $63.33.

Institutional Trading of Bristol Myers Squibb

Institutional investors and hedge funds have recently made changes to their positions in the company. New England Asset Management Inc. lifted its holdings in shares of Bristol Myers Squibb by 0.8% during the 1st quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company's stock worth $2,408,000 after acquiring an additional 305 shares during the period. Commonwealth Equity Services LLC lifted its stake in Bristol Myers Squibb by 1.1% in the 1st quarter. Commonwealth Equity Services LLC now owns 1,288,407 shares of the biopharmaceutical company's stock valued at $78,580,000 after purchasing an additional 13,959 shares during the last quarter. Sage Capital Advisors llc lifted its stake in Bristol Myers Squibb by 60.7% in the 2nd quarter. Sage Capital Advisors llc now owns 85,234 shares of the biopharmaceutical company's stock valued at $3,946,000 after purchasing an additional 32,181 shares during the last quarter. Ransom Advisory Ltd bought a new position in Bristol Myers Squibb in the 1st quarter valued at approximately $843,000. Finally, Castle Rock Wealth Management LLC lifted its stake in Bristol Myers Squibb by 458.2% in the 2nd quarter. Castle Rock Wealth Management LLC now owns 44,559 shares of the biopharmaceutical company's stock valued at $2,088,000 after purchasing an additional 36,576 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.09% of the company's stock.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.7%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio is 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.